by Halia Therapeutics | Jan 17, 2024 | News & Media
Biotech Acquisitions Heat Up, Giving Venture Capitalists Hope for 2024 ‘Investors and entrepreneurs also are wrestling with questions such as the impact of the 2022 Inflation Reduction Act, which enabled Medicare to negotiate prices of certain medications, said... by Halia Therapeutics | Jan 11, 2024 | News & Media
January 11th, 2024 Author: Danny Sullivan Dr. David Bearss was featured in Longevity.Technology discussing Halia Therapeutics moving into multiple Phase 2 trials for chronic inflammation and whether the company may have created a ‘longevity drug.’ Fresh from... by Halia Therapeutics | Jan 4, 2024 | News & Media
Alternative Funding Strategies to Discuss at JPM The last year has demonstrated that a sound financing strategy and compelling company narrative are essential to securing funding – it’s become more important than ever that investors are excited before taking the... by Halia Therapeutics | Jan 4, 2024 | Press Releases
LEHI, Utah, Jan. 4, 2024 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company, is pioneering a novel class of small molecule medications designed to combat inflammation. Today, the company announced that its leadership team will attend... by Halia Therapeutics | Dec 15, 2023 | Press Releases
LEHI, Utah, Dec. 15, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced that the company will present at the 13th...